Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 343 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Observation for safety Clear all

Conditions: Peripheral Nerve Injuries
Interventions: Nerve Cap; Device
Lead sponsor: Tulavi Therapeutics,Inc.; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Redwood City, California • Englewood, Colorado • Orlando, Florida + 2 more

Conditions: Hyperphosphatemia
Interventions: Lanthanum carbonate; Drug
Lead sponsor: Shire; Industry
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Lynwood, California • Torrance, California • Springfield, Massachusetts + 5 more

Conditions: Chronic Thromboembolic Pulmonary Hypertension
Interventions: Macitentan, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 20 more

Conditions: Peyronie's Disease
Interventions: Subjects Previously Treated with AA4500; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Anchorage, Alaska • Burbank, California • Laguna Hills, California + 27 more

Conditions: Fibrosing Colonopathy
Interventions: ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy; Biological · Other
Lead sponsor: AbbVie; Industry
Eligibility: 0 Months to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 123
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more

Conditions: Pregnancy, Obesity, Overweight
Interventions: No Intervention; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 728 participants
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Spinal Cord Injuries
Interventions: Magnetic Resonance Imaging (MRI); Diagnostic Test
Lead sponsor: Lineage Cell Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 3
States / cities: Palo Alto, California • Atlanta, Georgia • Evanston, Illinois

Conditions: Graft vs Host Disease
Interventions: Atorvastatin calcium (Lipitor); Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Intestinal Health
Interventions: "Humanized" galacto-oligosaccharides (hGOS), Galacto-oligosaccharides (GOS), Matching Placebo; Dietary Supplement · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Burns
Interventions: ReCell® Autologous Cell Harvesting Device; Device
Lead sponsor: Avita Medical; Industry
Eligibility: 5 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 3 more

Conditions: Prostate Cancer, Hypogonadism, Male
Interventions: Testosterone cypionate; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Healthy Subjects
Interventions: AC-076 for s.c. administration, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Hepatitis C, Heroin Dependence
Interventions: Buprenorphine/naloxone, pegInterferon; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Oakland, California

Conditions: Odontalgia, Toothache
Interventions: Epidiolex 100 mg/mL Oral Solution, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Psoriasis (PsO)
Interventions: Deucravacitinib, Other systemic treatments for PsO; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Female only
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Systemic Lupus Erythematosus
Interventions: Benlysta, Standard of Care (SoC) Therapy; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 3,138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 102
States / cities: Birmingham, Alabama • Glendale, Arizona • Goodyear, Arizona + 85 more

Conditions: Liver Neoplasms, Hepatic Cirrhosis, Hepatic Carcinoma, Liver Cancer, Liver Metastases, Liver Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatic Atrophy
Interventions: Ferumoxytol injection; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Frequent Heartburn
Interventions: Rabeprazole sodium; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 33
States / cities: Scottsdale, Arizona • Griffin, Georgia • Lawrenceville, Georgia + 29 more

Conditions: Infectious Diseases
Interventions: Ciprofloxacin, Non-quinolone antibiotic; Drug
Lead sponsor: Bayer; Industry
Eligibility: 2 Months to 16 Years
Enrollment: 1,029 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 66
States / cities: Mobile, Alabama • Fort Smith, Arkansas • Corona, California + 58 more

Conditions: Health Behavior
Interventions: Hydrate Philly; Behavioral
Lead sponsor: Philadelphia Department of Public Health; Government
Eligibility: 3 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tibial Fractures
Interventions: Not listed
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Athens, Georgia • Fort Worth, Texas

Conditions: Prion Disease
Interventions: PrP-siRNA; Drug
Lead sponsor: Broad Institute of MIT and Harvard; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Rochester, Minnesota • New York, New York + 2 more

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: Memantine XR-pregabalin combination therapy; Drug
Lead sponsor: Saint John's Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions: Light-activated AU-011, Laser Activation; Drug · Device
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 13
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more

Search by objective public record fields.

Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success Study

Long-term Effect of Lanthanum Carbonate on Bone

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

LTFU Study of Subjects Who Received GRNOPC1

Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation

Safety, Tolerability, and Biosignature of Humanized Prebiotics in Healthy Adults

Continued Access to the Recell® Device for Treatment of Acute Burn Injuries

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1

CBD for Dental Pain

A Study to Assess Deucravacitinib Safety in Pregnancy

Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms

BAY 0 9867 Cipro Pediatric Use Study (QUIP)

Increasing Water Access and Appeal in Community Recreation Centers

Safety Study of Treatment of Leg Fractures

PrP-targeting siRNA Safety & Mechanism Study

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

Study in Subjects With Small Primary Choroidal Melanoma